THE USE OF ANTI-CYTOKINE PROPERTIES OF THE DOMESTIC HEMOSORBENT HEMO-PROTEASOSORB IN CYTOKINE STORM IN PATIENTS WITH SEVERE COVID-19
Background: The urgency of the problem of treating a severe form of COVID-19 is due to the high mortality rate among patients in intensive care units (more than 25.8%). One of the main contributors to the severe course of the disease is the cytokine storm caused by the release of a large concentration of pro-inflammatory cytokines into the bloodstream. In addition to the drug-induced blockade of this condition, extracorporeal elimination can also be considered as an effective method for suppressing the clinical manifestations of cytokine aggression. Purpose: To assess the possibility of extracorporeal removal of cytokines by hemosorption through the Hemo-proteasosorb sorbent in patients with severe COVID-19 accompanied by cytokine storm. Material and methods: A clinical and laboratory assessment of the course of the disease was made in 12 patients with a severe form of COVID-19 who developed the cytokine storm associated with hemosorption. Results: After hemosorption, a statistically significant decrease in the level of IL-6, neutrophils, procalcitonin and D-dimers was established. There was also observed an improvement in the oxygen transport function of the blood represented by an increase in the respiratory index. Conclusion: Hemisorption through the Hemo-proteasosorb sorbent can be effectively used to suppress the cytokine storm in patients with severe COVID-19.